Volume 9 Issue 4 | Blood Advances | American Society of Hematology

Skip Nav Destination

Red Cells, Iron, and Erythropoiesis

Donor age contributes more to the rheological properties of stored red blood cells than donor sex and biological age distribution

Olga Mykhailova,Mackenzie Brandon-Coatham,Sanaz Hemmatibardehshahi,Mahsa Yazdanbakhsh,Carly Olafson,Qi-Long Yi,Tamir Kanias,Jason P. Acker

View Articletitled, Donor age contributes more to the rheological properties of stored red blood cells than donor sex and biological age distribution

Supplemental data

How donor age affects RBC deformability in storage

Kerryn Matthews,Hongshen Ma

View Articletitled, How donor age affects RBC deformability in storage

ADVANCES VIEWPOINT

The roadmap to integrate diversity, equity, and inclusion in hematology clinical trials: an American Society of Hematology initiative
Clinical Trials & Observations

View Articletitled, The roadmap to integrate diversity, equity, and inclusion in hematology clinical trials: an American Society of Hematology initiative

Supplemental data

New strategies for enhancing enrollment of underrepresented minorities in lymphoma clinical trials

Chijioke Nze,Alex F. Herrera

View Articletitled, New strategies for enhancing enrollment of underrepresented minorities in lymphoma clinical trials

Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?

Richard J. Jones,Adetola A. Kassim,Robert A. Brodsky,Michael R. DeBaun

View Articletitled, Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?

The transplant debate: defining innovation for sickle cell

Cécile Karsenty,Titilope Fasipe,Alexander I. Ngwube

View Articletitled, The transplant debate: defining innovation for sickle cell

CLINICAL TRIALS AND OBSERVATIONS

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
Clinical Trials & Observations

View Articletitled, Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas

Supplemental data

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
Clinical Trials & Observations

Benjamin M. Heyman,Stephen S. Opat,Björn E. Wahlin,Meletios-Athanasios C. Dimopoulos,Jorge J. Castillo,Alessandra Tedeschi,Constantine S. Tam,Christian Buske,Roger G. Owen,Véronique Leblond,Judith Trotman,Gisoo Barnes,Wai Y. Chan,Jingjing Schneider,Heather Allewelt,Aileen Cohen,Jeffrey V. Matous

View Articletitled, Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies
Clinical Trials & Observations

Matthew S. Davids,Danielle M. Brander,Yesid Alvarado-Valero,Catherine S. Diefenbach,Daniel N. Egan,Shira N. Dinner,Nathalie Javidi-Sharifi,Monzr M. Al Malki,Kebede H. Begna,Vijaya Raj Bhatt,Sameem Abedin,Rachel J. Cook,Mary C. Collins,Carly Roleder,Edward C. Dominguez,Prabhu Rajagopalan,Sandra E. Wiley,Richard G. Ghalie,Alexey V. Danilov

View Articletitled, A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

Supplemental data

Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia
Clinical Trials & Observations

View Articletitled, Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia

Supplemental data

Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome
Clinical Trials & Observations

View Articletitled, Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome

Supplemental data

Prognostic impact of patient-reported symptoms in multiple myeloma
Clinical Trials & Observations

Nadine Abdallah,Arwa Bohra,Aytaj Mammadzadeh,Francis Buadi,Prashant Kapoor,Angela Dispenzieri,Morie Gertz,Suzanne Hayman,Mohammed ElHaj,David Dingli,Joselle Cook,Moritz Binder,Yi Lin,Taxiarchis Kourelis,Rahma Warsame,Carrie Thompson,Terri Menser,S. Vincent Rajkumar,Shaji Kumar

View Articletitled, Prognostic impact of patient-reported symptoms in multiple myeloma

Supplemental data

Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort study
Clinical Trials & Observations

Elisabeth Reuben Tolley,Torsten Holm Nielsen,Ditte Stampe Hersby,Simon Østergaard,Malin Rasmussen,Michael Roost Clausen,Ahmed Ludvigsen Al-Mashhadi,Karina Moeslund Egeberg,Laura Mors Haunstrup,Christian Brieghel,Carsten Utoft Niemann,Tarec Christoffer El-Galaly,Lars Møller Pedersen

View Articletitled, Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort study

Supplemental data

Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates
Clinical Trials & Observations

Ana Rita da Fonseca,Caio Cesar Justino,Vinicius Campos de Molla,Patricia Eiko Yamakawa,Iara Baldim Rabelo,Louise Arnold,Richard Kelly,Morag Griffin,Talha Munir,Anita Hill,Elvira Velloso,Thales Dalessandro,Antonio M. Risitano,Phillip Scheinberg,Austin Kulasekararaj,Celso Arrais-Rodrigues

View Articletitled, Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates

REVIEW ARTICLE

Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma

Gustavo de Oliveira Canedo,Claire Roddie,Persis J. Amrolia

View Articletitled, Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma

CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?

Nicola Maciocia,Brandon Wade,Paul Maciocia

View Articletitled, CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?

Supplemental data

THROMBOSIS AND HEMOSTASIS

Membrane-bound model of the ternary complex between factor VIIa/tissue factor and factor X

Melanie P. Muller,Alex Mortenson,Josepha C. Sedzro,Po-Chao Wen,James H. Morrissey,Emad Tajkhorshid

View Articletitled, Membrane-bound model of the ternary complex between factor VIIa/tissue factor and factor X

Supplemental data

TRANSPLANTATION

Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM
Clinical Trials & Observations

View Articletitled, Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM

Supplemental data

MYELOID NEOPLASIA

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS

View Articletitled, Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS

Chronic inflammation deters natural killer cell fitness and cytotoxicity in myeloid leukemia

Valeriya Kuznetsova,Vaidehi Krishnan,Amanda Costa,Xi Ren,Tiffany D. Ricketts,Sweta B. Patel,Ashley N. Connelly,Paran Goel,Joshua P. Knapp,Alana M. Franceski,Francesca Luca,Lorena Lobo de Figueiredo-Pontes,Ravi Bhatia,Shyam Prabhakar,S. Tiong Ong,Robert S. Welner

View Articletitled, Chronic inflammation deters natural killer cell fitness and cytotoxicity in myeloid leukemia

Supplemental data

Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy

Wei-Ying Jen,Koji Sasaki,Farhad Ravandi,Tapan M. Kadia,Sa A. Wang,Wei Wang,Sanam Loghavi,Naval G. Daver,Courtney D. DiNardo,Ghayas C. Issa,Hussein A. Abbas,Cedric Nasnas,Alex Bataller,Samuel Urrutia,Omer S. Karrar,Sherry Pierce,Hagop M. Kantarjian,Nicholas J. Short

View Articletitled, Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy

Supplemental data

Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis

View Articletitled, Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis

Supplemental data

TIFAB modulates metabolic pathways in KMT2A::MLLT3−induced AML through HNF4A

Yang Wang,Yan Xiu,Qianze Dong,Jinming Zhao,Kelao Neumbo,Masaru Miyagi,Nicholas Borcherding,Lin Fu,Havana De Celis,Nicolas Pintozzi,Daniel T. Starczynowski,Chen Zhao

View Articletitled, TIFAB modulates metabolic pathways in KMT2A::MLLT3−induced AML through HNF4A

Supplemental data

RESEARCH LETTER

Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm
Clinical Trials & Observations

Sabine Khalife-Hachem,Arnaud Pages,Elie Akoury,Sarah Bonnet,Rudy Birsen,Clémence Busquet,Adrien Contejean,Alina Danu,Stéphane de Botton,Marie de Charette,Pierre Yves Dumas,Arnaud Jaccard,Anne Marfaing-Koka,Christophe Willekens,Eric Deconinck,David Ghez

View Articletitled, Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm

Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathies

Tusneem Janoudi,Mrunali Jagdale,Meng Wu,Sanjana Gorlla,Peisheng Zhang,Ying Shao,Li Li,Sheryl R. Bowley,Eugenio Marco,Kai-Hsin Chang

View Articletitled, Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathies

Supplemental data

Genomic landscape of testicular follicular lymphoma is characterized by frequent 1p36/TNFRSF14 alterations

Weiwei Zhang,Anamarija M. Perry,Hans Magne Hamnvåg,Sumire K. Kitahara,Sarah L. Ondrejka,Alexandra E. Kovach,Ji Yuan,Krystie Chew,Julia Davidson,Victoria Bedell,Jamie L. Stokke,Joo Y. Song

View Articletitled, Genomic landscape of testicular follicular lymphoma is characterized by frequent 1p36/TNFRSF14 alterations

Supplemental data

Testicular follicular lymphoma: let me count the ways

Elaine S. Jaffe,Leticia Quintanilla-Martinez

View Articletitled, Testicular follicular lymphoma: let me count the ways

Fusion-specific chromatin profiles mediate transcriptional heterogeneity in MLL-rearranged acute lymphoblastic leukemia

Shan Lin,Michael Kotliar,Sushmitha Vallabh,Anetta Ptasinska,Salam A. Assi,Mark Wunderlich,Constanze Bonifer,Artem Barski,James C. Mulloy

View Articletitled, Fusion-specific chromatin profiles mediate transcriptional heterogeneity in MLL-rearranged acute lymphoblastic leukemia

Supplemental data

Inside Blood Advances

How donor age affects RBC deformability in storage

Kerryn Matthews,Hongshen Ma

View Articletitled, How donor age affects RBC deformability in storage

Testicular follicular lymphoma: let me count the ways

Elaine S. Jaffe,Leticia Quintanilla-Martinez

View Articletitled, Testicular follicular lymphoma: let me count the ways

The transplant debate: defining innovation for sickle cell

Cécile Karsenty,Titilope Fasipe,Alexander I. Ngwube

View Articletitled, The transplant debate: defining innovation for sickle cell

Lymphoid Neoplasia

Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience

Steven R. Hwang,Richard C. Godby,Brianna J. Negaard,Raphael Mwangi,Adrienne N. Nedved,Jason N. Barreto,Ivana N. Micallef,Stephen M. Ansell,Luis Porrata,Urshila Durani,Gita Thanarajasingam,Thomas M. Habermann,Matthew J. Maurer,Patrick B. Johnston,Arushi Khurana

View Articletitled, Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience

Issue Archive

Red Cells, Iron, and Erythropoiesis

ADVANCES VIEWPOINT

The roadmap to integrate diversity, equity, and inclusion in hematology clinical trials: an American Society of Hematology initiative Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas Clinical Trials & Observations

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia Clinical Trials & Observations

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies Clinical Trials & Observations

Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia Clinical Trials & Observations

Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome Clinical Trials & Observations

Prognostic impact of patient-reported symptoms in multiple myeloma Clinical Trials & Observations

Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort study Clinical Trials & Observations

Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates Clinical Trials & Observations

REVIEW ARTICLE

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM Clinical Trials & Observations

MYELOID NEOPLASIA

RESEARCH LETTER

Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm Clinical Trials & Observations

Inside Blood Advances

Lymphoid Neoplasia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

The roadmap to integrate diversity, equity, and inclusion in hematology clinical trials: an American Society of Hematology initiative
Clinical Trials & Observations

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
Clinical Trials & Observations

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
Clinical Trials & Observations

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies
Clinical Trials & Observations

Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia
Clinical Trials & Observations

Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome
Clinical Trials & Observations

Prognostic impact of patient-reported symptoms in multiple myeloma
Clinical Trials & Observations

Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort study
Clinical Trials & Observations

Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates
Clinical Trials & Observations

Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM
Clinical Trials & Observations

Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm
Clinical Trials & Observations